Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1710340 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $49.03Day +1.87%Mkt cap $1.3B1Y +237.7%Off 52W high −2.3%Vol (1Y) 56.2%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,933 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.5% of sh out |
| Days to cover3.0d |
| 13F net flow (QoQ)+1.65% |
| Top-10 13F concentration64.5% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$86.9M |
| Earnings (TTM)-$1.5M |
| ROE−18.2% |
| Net margin−5.8% |
| ROIC−1.9% |
| Debt / equity1.17× |
| Total debt / EBITDA9.55× |
| Sales growth 3Y55.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+189.9% |
| 1Y+237.7% |
| 3Y+1638.7% |
| 5Y+853.9% |
| Since incept. (ann.)+30.6% |
Total return through 2026-07-30 · series begins 2018-11-13. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)56.2% |
| Ann. volatility (3Y)65.7% |
| Sharpe (1Y)2.48 |
| Sharpe (3Y)1.78 |
| Max drawdown (1Y)−36.2% |
| Max drawdown (3Y)−45.6% |
| Beta (3Y vs SPY)−0.46 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Opaleye Management Inc. | 2.9M | $71M | 10.48% | +0.0% |
| EcoR1 Capital, LLC | 2.2M | $54M | 7.96% | +7.0% |
| BlackRock, Inc. | 1.7M | $42M | 6.29% | −1.2% |
| Nantahala Capital Management, LLC | 1.2M | $29M | 4.31% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 994,089 | $25M | 3.64% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 577,666 | $14M | 2.12% | +2.2% |
| STATE STREET CORP | 530,215 | $13M | 1.94% | +5.6% |
| National Philanthropic Trust | 492,112 | $12M | 1.80% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $0.05 | — | $24.3M | +40.4% |
| 2025-12-31 | 2026-03-19 | — | — | $21.3M | +82.7% |
| 2025-09-30 | 2025-11-06 | −$0.07 | −450.0% | $22.5M | +117.5% |
| 2025-06-30 | 2025-08-07 | — | — | $18.9M | +108.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product Sales And Royalties 96% · License 4%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
